About

Anjay Rastogi, MD, PhD is a Professor and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA. He is board certified in Nephrology and holds a doctoral degree in Pharmacology. Dr. Rastogi completed his Internal Medicine residency and Nephrology fellowship at UCLA, where he also did his graduate training under the mentorship of Nobel Laureate Professor Louis Ignarro. He is the founder and Director of the UCLA CORE Kidney Health Program, which emphasizes clinical excellence, outreach, research, and education. Dr. Rastogi is heavily involved in research and serves as the Director of the Nephrology Clinical Research Program and multiple other programs at UCLA dedicated to providing comprehensive and integrated care to patients and their families. He founded the Bruin Beans Health Club at UCLA, an undergraduate organization aimed at mentoring future healthcare leaders. Recognized for his contributions, he received the UCLA Exceptional MD of the Year Award in 2014 and has been listed among Super Doctors and Top Doctors in Los Angeles multiple times. His research interests include chronic kidney disease, end-stage kidney disease, diabetic kidney disease, and various genetic and acquired nephropathies, with a focus on improving patient outcomes through clinical care and research.

Research topics

• Medicine
• Internal medicine
• Cardiology
• Intensive care medicine
• Radiology
• Endocrinology
• Pathology
• Physical therapy
• Bioinformatics
• Biology
• Urology
• Chemistry
• Pharmacology

Selected publications

• Targeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

  Kidney International · 2026-03-01

  article
  PublisherDOI

• Correction: Practice patterns on the management of secondary hyperparathyroidism in the United States: Results from a modified Delphi panel

  PLoS ONE · 2025-04-22

  erratumOpen access

  [This corrects the article DOI: 10.1371/journal.pone.0266281.].

  PublisherOA PDFDOI

• Vonafexor in Progressive Alport Syndrome: Early Evidence of Kidney Function Benefit from the ALPESTRIA-1 Trial

  Journal of the American Society of Nephrology · 2025-10-01

  article
  PublisherDOI

• Practice patterns on the management of secondary hyperparathyroidism in the United States: Results from a modified Delphi panel

  PLoS ONE · 2025-01-31 · 1 citations

  articleOpen accessCorresponding

  BACKGROUND: Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney disease (CKD). Many recommendations in the Kidney Disease Improving Global Outcomes (KDIGO) CKD-mineral and bone disorder guidelines are supported by modest evidence and predate the approval of newer agents. Therefore, an expert panel defined consensus SHPT practice patterns in the United States with real-world context from the nephrology community. METHODS: Ten US healthcare providers and one patient participated in a modified Delphi method comprising three phases. Consensus was determined via iterative responses to a questionnaire based on the 2009 and 2017 KDIGO guidelines and published literature on the identification, evaluation, monitoring, and interventional strategies for patients with SHPT. The threshold for consensus was 66% agreement. RESULTS: Panelists generally agreed with KDIGO recommendations, with some differences. Consensus was reached on 42/105 (40%), 95/105 (90.5%), and 105/105 (100%) questions after phases 1, 2, and 3, respectively. Panelists unanimously agreed that SHPT treatment is often started late. There was a preference for serum phosphate level <4.6 mg/dL, and consensus to maintain serum calcium levels <9.5 mg/dL. There was unanimous agreement for vitamin D analogues as first-line options in patients not on dialysis with severe, progressive SHPT and unanimous preference for intravenous calcimimetic, etelcalcetide, in appropriate in-center dialysis patients. Factors such as formularies, dialysis center protocols, and insurance were recognized to influence therapeutic strategies. CONCLUSIONS: Expert consensus was reached on SHPT management, further defining therapeutic strategies and medication use and emphasizing need for treatment early. Despite evidence-based treatment preferences supported by clinical experience, factors other than scientific evidence influence decision making, particularly with medications.

  PublisherDOI

• Real-World (RW) Clinical Considerations for IgAN Treatment Decisions: Survey of Health Care Providers (HCPs) in the United States (US)

  Journal of the American Society of Nephrology · 2025-10-01

  articleSenior author
  PublisherDOI

• Association of Different Definitions of Erythropoiesis-Stimulating Agent Hyporesponsiveness with Major Adverse Cardiovascular Events

  Kidney360 · 2025-05-07 · 2 citations

  articleOpen access

  Key Points Among patients receiving maintenance dialysis, an inadequate hemoglobin response to erythropoiesis-stimulating agents (ESAs) is associated with a higher risk of adverse outcomes. Among patients in ASCEND-D, all three different prespecified definitions of ESA hyporesponsiveness were similarly associated with major adverse cardiovascular event outcomes. ESA hyporesponsiveness should be considered an important clinical parameter for risk-stratifying patients with kidney failure requiring dialysis. Background Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) is a common clinical problem and is associated with major adverse cardiovascular events (MACEs). Although several definitions have been proposed, data examining associations with MACE in clinical trials are limited. Methods Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D, NCT02879305), a large event-driven cardiovascular outcomes trial, randomized 2964 patients receiving maintenance dialysis to either daprodustat or conventional ESAs. All patients received an ESA for at least 6 weeks before randomization and were managed with dosing algorithms for iron and randomized treatment. Three definitions of ESA hyporesponsiveness were prespecified: ( 1 ) ESA hyporesponsiveness definition 1 (HypoR1): an erythropoietin resistance index ≥2 U/kg per week per gram per liter or prior ESA dose/estimated dry weight ≥450 U/kg per week, ( 2 ) ESA hyporesponsiveness definition 2 (HypoR2): erythropoietin resistance index ≥1.5 U/kg per week per gram per liter, and ( 3 ) ESA hyporesponsiveness definition 3 (HypoR3): baseline ESA dose (U/wk) in top 20th percentile. Adjusted Cox regression models were fit to examine the association of each definition with the adjudicated MACE composite (death, nonfatal myocardial infarction, and nonfatal stroke). Results Baseline ESA hyporesponsiveness was present in 12%, 20%, and 20% of patients according to definitions HypoR1, HypoR2, and HypoR3, respectively. Compared with those without hyporesponsiveness, all definitions were associated with a higher risk of the composite MACE outcome: adjusted hazard ratio (HR) 1.32 (95% confidence interval [CI], 1.04 to 1.68) for HypoR1, HR 1.33 (95% CI, 1.08 to 1.63) for HypoR2, and HR 1.36 (95% CI, 1.12 to 1.66) for HypoR3. There was no evidence for effect modification by randomized treatment ( P interaction &gt; 0.40 for all). Conclusions Baseline ESA hyporesponsiveness is a potent predictor of MACE among patients receiving maintenance dialysis in ASCEND-D. All prespecified definitions were similarly associated with a higher risk of MACE. Clinical Trial registry name and registration number: NCT02879305.

  PublisherDOI

• Fabry Disease: Are We Looking Hard Enough?

  Kidney News · 2025-07-08

  article1st authorCorresponding
  PublisherDOI

• Cardiovascular Complications in ADPKD

  Kidney International Reports · 2025-07-05 · 1 citations

  reviewOpen access

  gene, is among the most common hereditary kidney diseases worldwide and is associated with significant extrarenal manifestations, including cardiovascular disease. In patients with ADPKD, cardiovascular disease is the major cause of mortality and is associated with a high burden of comorbidities. Cardiovascular manifestations include hypertension, which may lead to left ventricular hypertrophy (LVH) and diastolic dysfunction, as well as valvular abnormalities, aortic aneurysm, and pericardial effusion (PCE). The cardiovascular manifestations can present early as part of the ADPKD manifestation or later because of chronic kidney disease (CKD) progression. Early detection of cardiovascular manifestations can play a pivotal role in better management of these patients. Hypertension in ADPKD might start at an early age and is driven by a complex interplay of polycystin (PC) dysfunction, intracellular signaling disruptions, and activation of the renin-angiotensin-aldosterone system (RAAS), which can contribute to vascular structural changes and impaired endothelial function. Valvular involvement exhibits a bimodal pattern of age distribution, with early manifestations occurring in younger patients likely linked to genetic factors and later complications emerging as part of CKD progression. This review explores cardiovascular complications in ADPKD, emphasizing the need for early detection, and briefly provides an overview of tailored management approaches to improve outcomes in this high-risk population.

  PublisherOA PDFDOI

• Real-World (RW) Insights on How Health Care Providers (HCPs) Define Glomerular Inflammation in IgAN in the United States (US)

  Journal of the American Society of Nephrology · 2025-10-01

  articleSenior author
  PublisherDOI

• Anemia Management in Home Hemodialysis

  2024-01-01

  book-chapter
  PublisherDOI

Frequent coauthors

• Srinivasan Beddhu

  VA Salt Lake City Healthcare System

  287 shared

• Alfred K. Cheung

  University of Utah

  249 shared

• Michael V. Rocco

  Wake Forest University

  246 shared

• Mahboob Rahman

  238 shared

• Vasilios Papademetriou

  Georgetown University Medical Center

  235 shared

• James P. Lash

  Northwestern University

  234 shared

• Amret Hawfield

  234 shared

• Raymond R. Townsend

  233 shared

Education

• M.D.

  Not provided

• Ph.D.

  Not provided

Awards & honors

• Super doctors, Southern California, 2026
• Top doctors, Los Angeles Magazine's Top Doctors 2025
• Super Doctors® Southern California, 2023 - 2026
• Top Doctors, Los Angeles Magazine, 2024, 2025
• Top Doctors, Los Angeles Magazine, 2019, 2020, 2021, 2023